GHRP-2 vs GHRP-6 vs Sermorelin
A three-way comparison to help you find the right peptide for your research goals.
GHRP-2
Growth Hormone Releasing Peptide 2 (GHRP-2) is considered one of the most potent GHRPs available. It provides strong GH release with moderate hunger increase compared to GHRP-6.
Full details →GHRP-6
Growth Hormone Releasing Peptide 6 (GHRP-6) is one of the first synthetic growth hormone secretagogues discovered. It stimulates significant GH release but is known for causing intense hunger.
Full details →Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Side-by-Side Comparison
| Aspect | GHRP-2 | GHRP-6 | Sermorelin |
|---|---|---|---|
| Dose Range | 100 mcg–300 mcg | 100 mcg–300 mcg | 100 mcg–300 mcg |
| Frequency | 3x daily | 3x daily | 1x daily |
| Cycle Length | 8–12 weeks | 8–12 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous | subcutaneous |
| Mechanism | Binds to the ghrelin receptor (GHS-R) to stimulate GH release from the pituitary. Also has some direct effects on the hypothalamus. Causes less appetite increase than GHRP-6. | Acts as a ghrelin mimetic, binding to the GHS-R receptor in the pituitary and hypothalamus. Stimulates GH release and also significantly increases appetite by mimicking ghrelin's hunger-signaling effects. | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily. Often stacked with GHRH peptides for enhanced GH release. | Typical dosing: 100-300mcg administered 2-3 times daily. Often combined with GHRH peptides like CJC-1295 for synergistic effects. | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. |
| Administration | Subcutaneous injection on an empty stomach. Can be used at bedtime to enhance natural GH pulse during sleep. | Subcutaneous injection. Best administered on an empty stomach. The strong hunger response can be beneficial for those trying to gain weight but challenging for cutting. | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. |
| Side Effects | Moderate hunger increase, water retention, potential prolactin and cortisol elevation (less than GHRP-6), tingling sensations. | Intense hunger (most notable effect), water retention, increased cortisol and prolactin, tingling/numbness, and potential blood pressure changes. | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. |
| Best For |
What They Have in Common
GHRP-2, GHRP-6, Sermorelin are all commonly used for:
Key Differences
Unique to GHRP-2:
Unique to GHRP-6:
Unique to Sermorelin:
Which Has Stronger Evidence?
| Goal | GHRP-2 | GHRP-6 | Sermorelin |
|---|---|---|---|
| Muscle Growth | high | high | medium |
Key Studies
GHRP-2
- On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse.
Drug testing and analysis, 2021
- Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation.
PloS one, 2016
- Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice.
Peptides, 2014
GHRP-6
- Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.
Journal of nanobiotechnology, 2025
- Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.
Frontiers in pharmacology, 2024
- [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle.
Molecular and cellular endocrinology, 2015
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
Ready to Learn More?
Looking for trusted sources?